» Articles » PMID: 35330161

Genetic Landscape of Peripheral T-Cell Lymphoma

Overview
Journal Life (Basel)
Specialty Biology
Date 2022 Mar 25
PMID 35330161
Authors
Affiliations
Soon will be listed here.
Abstract

Peripheral T-Cell lymphoma (PTCL) comprises a heterogenous group of uncommon lymphomas derived from mature, post-thymic or "peripheral" T- and natural killer cells. The World Health Organization (WHO) emphasizes a multiparameter approach in the diagnosis and subclassification of these neoplasms, integrating clinical, morphologic, immunophenotypic, and genetic features into the final diagnosis. Clinical presentation is particularly important due to histologic, immunophenotypic and genetic variations within established subtypes, and no convenient immunophenotypic marker of monoclonality exists. In recent years, widespread use of gene expression profiling and next-generation sequencing (NGS) techniques have contributed to an improved understanding of the pathobiology in PTCLs, and these have been incorporated into the 2016 revised WHO classification of mature T- and NK-cell neoplasms which now encompasses nearly 30 distinct entities. This review discusses the genetic landscape of PTCL and its role in subclassification, prognosis, and potential targeted therapy. In addition to discussing T-Cell lymphoma subtypes with relatively well-defined or relevant genetic aberrancies, special attention is given to genetic advances in T-Cell lymphomas of T follicular helper cell (TFH) origin, highlighting genetic overlaps between angioimmunoblastic T-Cell lymphoma (AITL), follicular T-Cell lymphoma, and nodal peripheral T-Cell lymphoma with a TFH phenotype. Furthermore, genetic drivers will be discussed for ALK-negative anaplastic large cell lymphomas and their role in differentiating these from CD30+ peripheral T-Cell lymphoma, not otherwise specified (NOS) and primary cutaneous anaplastic large cell lymphoma. Lastly, a closer look is given to genetic pathways in peripheral T-Cell lymphoma, NOS, which may guide in teasing out more specific entities in a group of T-Cell lymphomas that represents the most common subcategory and is sometimes referred to as a "wastebasket" category.

Citing Articles

Peripheral T-Cell Lymphoma, Not Otherwise Specified: Diagnosis and Therapeutic Approaches for the Advanced Practice Provider.

Ow K, Vo A, Cunningham J J Adv Pract Oncol. 2024; :1-12.

PMID: 39563965 PMC: 11573116. DOI: 10.6004/jadpro.2024.15.8.3.


A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Kim W, Shortt J, Zinzani P, Mikhailova N, Radeski D, Ribrag V Clin Cancer Res. 2024; 31(1):65-73.

PMID: 39531538 PMC: 11701429. DOI: 10.1158/1078-0432.CCR-24-1913.


Genome-Wide Methylation Profiling of Peripheral T-Cell Lymphomas Identifies TRIP13 as a Critical Driver of Tumor Proliferation and Survival.

Nowialis P, Tobon J, Lopusna K, Opavska J, Badar A, Chen D Epigenomes. 2024; 8(3).

PMID: 39189258 PMC: 11348144. DOI: 10.3390/epigenomes8030032.


Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.

Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Garcia-Sancho A, Advani R Blood Adv. 2024; 8(17):4581-4592.

PMID: 38991123 PMC: 11401221. DOI: 10.1182/bloodadvances.2024012806.


Genetic alterations in mature B- and T-cell lymphomas - a practical guide to WHO-HAEM5.

Lopez C, Fischer A, Rosenwald A, Siebert R, Ott G, Kurz K Med Genet. 2024; 36(1):59-73.

PMID: 38835967 PMC: 11006337. DOI: 10.1515/medgen-2024-2005.


References
1.
Hu Z, Medeiros L, Fang L, Sun Y, Tang Z, Tang G . Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol. 2017; 92(5):441-447. DOI: 10.1002/ajh.24679. View

2.
Lemonnier F, Cairns R, Inoue S, Li W, Dupuy A, Broutin S . The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci U S A. 2016; 113(52):15084-15089. PMC: 5206549. DOI: 10.1073/pnas.1617929114. View

3.
Syrykh C, Pericart S, Lamaison C, Escudie F, Brousset P, Laurent C . Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features. Cancers (Basel). 2021; 13(13). PMC: 8268319. DOI: 10.3390/cancers13133315. View

4.
Hapgood G, Savage K . The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015; 126(1):17-25. DOI: 10.1182/blood-2014-10-567461. View

5.
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadie M . Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol. 2017; 35(18):2008-2017. DOI: 10.1200/JCO.2016.71.2083. View